The Innovation Index was put together by stakeholders across industry and academia. The Index has two dimensions – Qualitative or perceptual, and Quantitative.

The qualitative index showed that India had improved from 2018 to 2021, from 4.02 to 5.26 (perceptual scores), contributed majorly by improvements in regulatory & policy landscape and research outcomes such as novel drugs and new modalities.

The quantitative index came out to be 2.46 in 2018 and 2.79 in 2021 respectively, with the improvement driven mostly by regulatory improvements and advances in capabilities, talent and infrastructure.

The Composite Pharma Innovation Index for India was calculated by combining the 2 indices as 3.08 in 2018, and 3.78 in 2021. This will serve as the benchmark to measure the progress in pharma innovation.

The Takeaways
The key focus areas that require attention are government and private funding support, global collaboration, and number of NMEs, NBEs, etc. registered from India.

The Indian pharma innovation index calculation exercise must be conducted periodically.